Article
Chemistry, Multidisciplinary
Shuojiong Pan, Jun Guan, Banruo Xianyu, Yizheng Tan, Tianyu Li, Huaping Xu
Summary: Self-assembled selenium-containing nanoparticles are developed to reverse NK cell exhaustion and enhance NK-cell-mediated immunotherapy, effectively inhibiting tumor growth.
ADVANCED MATERIALS
(2023)
Article
Oncology
Mireia Bachiller, Lorena Perez-Amill, Anthony Matthew Battram, Sebastian Ciro Carne, Amer Najjar, Els Verhoeyen, Manel Juan, Alvaro Urbano-Ispizua, Beatriz Martin-Antonio
Summary: This study demonstrates the important immunoregulatory role of CB-NK collaborating with CAR-T cells to enhance their antitumor activity. Combinatorial treatment based on CAR-T and CAR-NK cells or CB-NK and CAR-T cells showed that CB-NK required high doses for effectiveness, while a low number of CB-NK in the CAR-T product promoted early activation of CAR-T cells and enhanced anti-MM efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Minna Sivonen, Katja A. Sirvio, Sara Wojciechowski, Anssi Kailaanmaki, Satu Kaipainen, Aubrey Bailey, Martin Villalba, Tuija Kekarainen
Summary: In this study, we aimed to identify the optimal activation and expansion protocol for cytotoxic NK cells against glioblastoma in vitro. The results showed that the ex vivo proliferation capacity and functionality of NK cells were affected by multiple factors, including the donor, composition of starting material, cytokine combination, and the activation protocol. These findings could be utilized for upscaling clinical NK cell manufacturing.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Hongwen Li, Wenting Song, Zhaoming Li, Mingzhi Zhang
Summary: CAR-NK cell therapy represents a promising strategy in the treatment of malignant tumors, with advantages over CAR-T cell therapy, but still faces challenges and limitations.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Regina M. Young, Nils W. Engel, Ugur Uslu, Nils Wellhausen, Carl H. June
Summary: CD19 and BCMA-directed CAR T cells have shown remarkable efficacy in treating certain hematologic malignancies, but there are still unmet treatment needs. Next-generation CAR T cells will incorporate gene engineering and synthetic biology to improve functionality and persistence, and reduce treatment-related toxicities. Combining autologous CAR T cells with allogeneic cell treatment strategies targeting the tumor microenvironment will expand the impact of CAR T-cell therapies.
Review
Oncology
Qi Xiong, Jiao Zhu, Yong Zhang, Hongxin Deng
Summary: Glioblastoma is the most common and deadly malignant tumor in the central nervous system. Conventional treatments like surgery, radiotherapy, and chemotherapy have limited success with high recurrence rate and poor prognosis. CAR-T cell therapy has achieved significant success in blood cancers, but its application in solid tumors like glioblastoma still faces challenges. CAR-NK cell therapy, an alternative adoptive cell therapy, shows similar anti-tumor effects and has the potential to overcome some of the limitations of CAR-T cell therapy. This article provides an overview of the preclinical research on CAR-NK cells in glioblastoma and discusses the problems and challenges in its application.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Kaveh Hadiloo, Safa Tahmasebi, Abdolreza Esmaeilzadeh
Summary: Cancer treatment is a major challenge globally, but CAR-NKT cell therapy shows promise as an effective approach.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Rikang Wang, Weili Bao, Mouli Pal, Yunfeng Liu, Karina Yazdanbakhsh, Hui Zhong
Summary: This study identified the antimetastasis and pro-NK cell activity of IFN-IMo, identified FOXO1 as a key molecule for IFN-gamma driven monocyte differentiation and function, and found NR4A1 as an inhibitory molecule for IFN-IMo activity. It provided potential targets for developing superior monocytic cell therapy against cancer metastasis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Matthew Bell, Stephen Gottschalk
Summary: CAR T cell therapy is effective for hematological malignancies, but there is a need to improve its efficacy for solid tumors and brain tumors. Several approaches are being pursued to enhance the antitumor activity of CAR T cells, including augmenting signal 3 of T cell activation and improving the function of CAR T cells in the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Faroogh Marofi, Alaa S. Al-Awad, Heshu Sulaiman Rahman, Alexander Markov, Walid Kamal Abdelbasset, Yulianna Ivanovna Enina, Mahnaz Mahmoodi, Ali Hassanzadeh, Mahboubeh Yazdanifar, Max Stanley Chartrand, Mostafa Jarahian
Summary: CAR-NK cells, as an emerging cancer treatment, have various advantages in cancer immunotherapy, including better safety and adaptability, and the ability to improve attack on tumors and eliminate resistance. By targeting different antigens, CAR-NK cells are expected to achieve more effective anti-tumor responses.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, Andrew D. Hungler, Shayne E. Boucher, Navjot Kaur, Mohan C. Vemuri
Summary: Natural killer (NK) cells are a crucial part of the immune system, with the ability to kill virally infected and malignant cells. Current research is focused on testing the efficacy of NK cell therapy for cancer and exploring the use of CAR-NK for treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ye Li, Rafet Basar, Guohui Wang, Enli Liu, Judy S. Moyes, Li Li, Lucila N. Kerbauy, Nadima Uprety, Mohsen Fathi, Ali Rezvan, Pinaki P. Banerjee, Luis Muniz-Feliciano, Tamara J. Laskowski, Emily Ensley, May Daher, Mayra Shanley, Mayela Mendt, Sunil Acharya, Bin Liu, Alexander Biederstadt, Hind Rafei, Xingliang Guo, Luciana Melo Garcia, Paul Lin, Sonny Ang, David Marin, Ken Chen, Laura Bover, Richard E. Champlin, Navin Varadarajan, Elizabeth J. Shpall, Katayoun Rezvani
Summary: The activation of chimeric antigen receptor (CAR) in natural killer (NK) cells promotes the transfer of tumor-specific antigen from tumor cells to NK cells, resulting in decreased tumor antigen density and impaired CAR-NK cell targeting ability. This phenomenon can lead to self-recognition and continuous CAR-mediated engagement, causing cell death in NK cells expressing the trogocytic antigen (NKTROG+) and reduced NK cell responsiveness. However, a dual-CAR system that incorporates both an activating CAR against the tumor antigen and an inhibitory NK self-recognizing CAR can prevent trogocytic antigen-mediated cell death in NK cells, while maintaining activation signaling against the tumor antigen, thereby enhancing CAR-NK cell activity.
Article
Oncology
Corinna Haist, Zoe Poschinski, Arthur Bister, Michele J. Hoffmann, Camilla M. Grunewald, Alexandra Hamacher, Matthias Kassack, Constanze Wiek, Kathrin Scheckenbach, Helmut Hanenberg
Summary: The study successfully generated a high-affinity EGFR CAR construct and demonstrated its efficacy and specificity in combating head and neck squamous cell carcinoma and other solid cancers.
Article
Oncology
Mazyar Shadman
Summary: Mantle cell lymphoma remains incurable despite recent treatment advances, making individualized treatment crucial for patients. Early intervention based on high-risk features and disease progression stage is essential for improved treatment outcomes.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Cell & Tissue Engineering
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh
Summary: CAR-T therapy has been successful in treating various types of relapsed/refractory B-cell malignancies, but faces challenges when combating T-cell malignancies, including fratricide, T-cell aplasia, and product contamination. Further research and improvements are needed to address these obstacles and enhance CAR-T therapy in T-cell malignancies.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
